Neil Clendeninn - OncoGenex Pharmaceuticals Independent Director
Director
Dr. Neil James Clendeninn, M.D., Ph.D., is anIndependent Director of OncoGenex Pharmaceuticals, Inc. Additionally, he has served as a member of OncoGenex Technologies Inc.s Board of Directors since September 2004. Dr. Clendeninn served as Corporationrationrate Vice President, Head of Clinical Affairs of Agouron Pharmaceuticals, Inc., a biopharmaceutical company and a subsidiary of Pfizer Inc., a pharmaceutical company, from 1993 until his retirement in 2001 since 2008.
Age | 66 |
Tenure | 16 years |
Professional Marks | Ph.D |
Phone | 425 686-1500 |
Web | www.oncogenex.com |
OncoGenex Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (35.45) % which means that it has lost $35.45 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (76.41) %, meaning that it created substantial loss on money invested by shareholders. OncoGenex Pharmaceuticals' management efficiency ratios could be used to measure how well OncoGenex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Keith Meister | Yum Brands | 41 | |
Elane Stock | Yum Brands | 55 | |
Thomas Taylor | National Vision Holdings | 52 | |
Heather Cianfrocco | National Vision Holdings | 45 | |
Robert Vivian | Shake Shack | 61 | |
Jonathan Linen | Yum Brands | 70 | |
Thomas Ryan | Yum Brands | 62 | |
Edie Ames | The Cheesecake Factory | 51 | |
Erik Morris | Wingstop | 39 | |
Keith Barr | Yum Brands | 50 | |
Stephen Rothwell | National Vision Holdings | 38 | |
Felix Gernburd | National Vision Holdings | 30 | |
Peter Skala | Yum Brands | 60 | |
Randolph Peeler | National Vision Holdings | 53 | |
Lauren Hobart | Yum Brands | 51 | |
Anna Fieler | Shake Shack | 48 | |
Drew Thomson | National Vision Holdings | 44 | |
Justin Skala | Yum Brands | 57 | |
Thomas Nelson | Yum Brands | 57 | |
David Goebel | Wingstop | 67 | |
Massimo Ferragamo | Yum Brands | 58 |
Management Performance
Return On Equity | -76.41 | |||
Return On Asset | -35.45 |
OncoGenex Pharmaceuticals Leadership Team
Elected by the shareholders, the OncoGenex Pharmaceuticals' board of directors comprises two types of representatives: OncoGenex Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OncoGenex. The board's role is to monitor OncoGenex Pharmaceuticals' management team and ensure that shareholders' interests are well served. OncoGenex Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OncoGenex Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Cindy Jacobs, Executive Vice President Chief Medical Officer | ||
Patricia MD, VP of Clinical Devel. | ||
Neil Clendeninn, Independent Director | ||
John Bencich, CFO, Vice President | ||
Jim DeNike, IR Contact Officer | ||
Scott Cormack, Founder, CEO and President Treasurer, Secretary and Director | ||
Martin Mattingly, Independent Director | ||
Stewart Parker, Independent Director | ||
David Smith, Independent Director | ||
Jack Goldstein, Independent Chairman of the Board |
OncoGenex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OncoGenex Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -76.41 | |||
Return On Asset | -35.45 | |||
Current Valuation | (6.64 M) | |||
Shares Outstanding | 2.74 M | |||
Shares Owned By Insiders | 0.79 % | |||
Shares Owned By Institutions | 27.00 % | |||
Number Of Shares Shorted | 844.89 K | |||
Price To Earning | (0.61) X | |||
Price To Book | 0.55 X | |||
Gross Profit | 5.06 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in OncoGenex Stock
If you are still planning to invest in OncoGenex Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the OncoGenex Pharmaceuticals' history and understand the potential risks before investing.
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Bonds Directory Find actively traded corporate debentures issued by US companies |